

A peculiar fibroma-like lesion of superficial soft tissue: morphologic and immunophenotypic evaluation

M. FILOTICO¹, A. DAMURI¹, R. FILOTICO²

¹ Anatomic Pathology Service, Card. Panico Foundation, Tricase, Italy; ² Dermatologic Unit, "Perrino" General Hospital; Brindisi, Italy

Key words

Mesenchymal tumours • Immunohistochemistry

Summary

A peculiar lesion of superficial soft tissue characterised by fibroma-like morphology and an immunohistochemical profile consisting of CK+, VIM+, CD34+, CD31+/-, FLI1+ and INI-1 retained is described. The lesion entered into differential diagnosis with the so-called fibroma-like variant of epithelioid sar-

coma, with the entities defined as ES-like/pseudomyogenic haemangioendothelioma and the recently identified entity defined as superficial CD34+ fibroblastic tumour. All of these entities share a common morphological structure, but differ in their immunophenotypic profile.

A 26-year-old man presented for a subcutaneous slow-growing, painless swelling on the left wrist lasting about two years. The patient was subjected to the surgical excision of the mass located in subcutaneous tissues, close to the tendons of the extensor muscles.

Materials and methods

At macroscopic examination, the surgical specimen was oval shaped, measured 1-8 x 1 cm, and the sectional area showed a pearly, homogeneous appearance. The outer surface was smooth. The formalin-fixed, paraffin-embedded sample was stained with haematoxylin-eosin and investigated with the following immunohistochemical antibodies: VIM (monoclonal 1:50 Dako), CK AE1-AE3 (monoclonal 1:50 Dako), EMA (monoclonal 1:50 Dako), SMACT (monoclonal 1:50 Dako), CALP (monoclonal 1:50 Dako), DESM (monoclonal 1:50 Dako), MYOGL (polyclonal 1:500 Sigma Aldrich), S100 (polyclonal 1:400 Dako), Ki-67 (monoclonal 1:75 Dako), CD34 (monoclonal 1:20 Dako), CD31 (monoclonal 1:20 Dako), INI-1 (polyclonal 1:500 Ventana Riche), FLI-1 (polyclonal 1:50 Santacruz Biotech).

Results

Histologic findings: a solid proliferation with a spindled cellular fibroblast-like component (Fig. 1a) was seen that was sometimes myoid-like (Fig. 1b). Among these elements pleomorphic, atypical cells with voluminous, hyperchromatic, irregular nucleus, sometimes multiple (Fig. 1c, d) were found with faintly acidophilic cytoplasm. Mitotic activity was virtually absent. The stroma was very loose and faintly fibrillar. The elements were assembled into variously oriented fascicles.

The results of immunohistochemistry are summarized in Table I and show the following immunophenotypic profile: CK+ (Fig. 2a), VIM+ (Fig. 2b), CD34+ (Fig. 2c), CD31 (Fig. 2d), INI-1-retained (Fig. 2e), and Fli-1+ (Fig. 2f).

Discussion

In the interpretation of this case numerous diagnostic hypotheses were considered that were progressively discarded.


The age of the patient, localisation of the lesion, its slow and indolent growth and the immunophenotypic profile,

Acknowledgements

The authors thank Dr. AP Dei Tos for collaboration in the interpretation of the lesion, Dr. Al Folpe for prompt reprints of his work, and Prof. J. Rosai for valuable advice.

Correspondence

M. Filotico, Anatomic Pathology Service, Card. Panico Foundation, via S. Pio X, 4 - 73039 Tricase (LE), Italy - E-mail: mfilotico@libero.it



characterized by the simultaneous expression of cytokeratin, vimentin and CD34, would support a diagnosis of epithelioid sarcoma (ES). The morphological structure, predominantly spindle-celled, is different from the classic description of this tumour, lacking the pseudo-granulomatous aspects, scalloped necrosis and the epithelioid cellular component.

Since 1992 there have been five cases with the same morphologic characteristics and simultaneously expressing VIM and CK reported in the literature. These lesions were labeled as “fibroma-like variants of ES”¹.

In 1999, in a review of 112 cases of ES, seven were attributed to the aforementioned variant², 50% of which had documented expression of CD34.

In 2003, seven cases with similar morphologic characteristics and expressing an immunophenotypic profile consisting of VIM+, CK+, CD34-, CD31+ and FLI-1+, were categorised as “ES-like haemangi endothelioma”³.

In the fifth edition of Enzinger & Weiss’s *Soft Tissue Tumors* (2008), two separate entities were reported; one was described as a fibroma-like variant of ES, and the other as ES-like haemangi endothelioma. The former is CD34+ and CD31-, and the latter CD34- and CD31+⁴.

In the same year, a brief report of 29 cases with the same morphology and immunophenotypic pattern (CK+, VIM+, CD34-, INI-1 intact) were considered to be “pseudomyogenic (fibroma-like) variants of ES”⁵.

In 2011, based on a study of 50 cases, the same authors, using a wider panel of antibodies, giving an immunophe-

notypic profile consisting of CK+ (100%), CD34+(0%), CD31+ (50%), FLI-1+ (100%), INI-1 intact (100%), redefined the lesion as “pseudomyogenic haemangi endothelioma”⁶. In a comment on this report in the same journal, in a Letter to the Editor⁷, the authors of an earlier report³ suggested that the morphologic and immunophenotypic identity of the lesion termed by them as ES-Like haemangi endothelioma was the same as the one called by the authors as pseudomyogenic haemangi endothelioma⁶.


Very recently a study entitled “Superficial CD34-Positive Fibroblastic Tumor”⁷ was published in which, on the basis of 18 cases, a peculiar neoplasm of the superficial soft tissues was described, hitherto not reported. The neoplasm was found in adult subjects, mainly located in the extremities, and was morphologically characterised by a fascicular growth pattern of spindled cells, with striking, often bizarre cellular pleomorphism. All cases showed strong, diffuse CD34 positivity, focal cytokeratin expression (69%), SMARGCB1 (INI-1) retained, and Ki-67 < 1%. S100, SM-act, desmin and FLI-1 were all negative. Thirteen patients were available for follow-up; 12 were alive without evidence of disease. Only one patient developed locoregional lymph node metastases seven years after marginal excision of the tumour. The authors concluded that this was a distinctive low-grade mesenchymal neoplasm of intermediate (borderline) malignancy.

A literature review shows that over time, around the core basis of a lesion morphologically defined as fibroma-like and immunophenotypically characterised by the simultaneous expression of CK and VIM, a variety of antibody associations have been created. Different denominations have also been assigned to such associations. The differences occur mainly in the expression of CD34, CD31, FLI-1 and INI-1. Currently, according to the Stanford’s criteria⁹, classic ES shows positivity for CD34 in 50% of cases, associated with loss of INI-1, and negativity for CD31 and FLI-1. In fact, in one of the aforementioned reports², 50% of the cases showed positivity for CD34 and negativity for CD31, consistent with classic ES. In other reports^{3,5,6}, constant negativity for CD34 is seen, associated with CD31+, FLI-1+ and INI-1 retained. From these data it is evident that it is justifiable in the first case the definition of fibroma-like ES and, conversely, in the second that of ES-Like/Pseudomyogenic Hemangi endothelioma. While on one hand the loss or retention of INI-1 is currently considered a discriminating element to establish or exclude an ES¹⁰, the expression of CD31 and FLI-1 supports an endothelial histogenesis^{11,12}. The recently described entity⁸ with its distinctive immunophenotypic profile (CK+, VIM+, CD34+, Ki-67 < 1%, FLI-1- and INI-1retained) adds a

Tab. I. Immunophenotypic profile.


VIM	CK	EMA	SMA	CALP	DESM	MYOGL	S100	Ki67	C34	CD31	INI1	FLI-1
+diff	+diff	rare	neg	neg	neg	neg	neg	<1%	+diff	+f	ret.	+diff

f: focal; diff: diffuse; neg: negative; ret: retained.



new subgroup to this complex group of lesions. With regards to the prognosis of these lesions, the literature does not mention differences between the classical form of ES and its fibroma-like variant, while the ES-like/pseudomyogenic haemangioendothelioma and the superficial CD34+ fibroblastic tumour are considered low-risk lesions (borderline).

Fibroma – like tumour group



Conclusions

The lesion that we observed with its immunophenotypic profile (CD34+, CD31+, FLI-1+, INI-1-retained) cannot be compared to any of the above-described fibroma-like entities with which it shares a common morphological structure for the following reasons: - It cannot be considered as a fibroma-like variant of ES because it has intact INI-1; It cannot be considered as an ES-like/pseudomyogenic haemangioendothelioma because it has intense expression of CD34. - It cannot be considered as a CD34+ fibroblastic tumour because it has intense expression of both CD31 and FLI-1. It is unclear if these various immunophenotypic expressions are indicative of different pathological entities or variants of a single entity, and further study will be needed to better to define this entity.

References

- Mirra JM, Kessler S, Bhuta S, et al. *The fibroma-like variant of Epithelioid Sarcoma a fibrohistiocytic/myoid cell lesion often confused with benign and malignant spindle cell tumors.* Cancer 1992;9:1382-95.
- Miettinen M, Fanburg-Smith JC, Virolainen M, et al. *Epithelioid Sarcoma: an immunohistochemical analysis of 112 classical and variant cases and a discussion of differential diagnosis.* Hum Pathol 1999;30:934-42.
- Billings SD, Folpe AL, Weiss SW. *Epithelioid Sarcoma-like Hemangioendothelioma.* Am J Surg Pathol 2003;27:48-57.
- Goldblum JR, Weiss SW, Folpe AL, Enzinger & Weiss's *Soft Tissue Tumors.* Fifth Edition. Elsevier Mosby 2008, pp. 698-700, 1193-6.
- Hornick JL, Fletcher CDM. *Pseudomyogenic ("fibroma-like") variant of Epithelioid sarcoma: a distinctive tumor type with propensity for multifocality in a single limb but surprisingly indolent behavior.* Mod Pathol 2008;21(Suppl 1):13.
- Hornick JL, Fletcher CDM. *Pseudomyogenic Hemangioendothelioma: a distinctive, often multicentric Tumor with indolent behavior.* Am J Surg Pathol 2011;35:190-201.
- Billings SD, Folpe AL, Weiss SW. *Epithelioid Sarcoma-like Hemangioendothelioma (pseudomyogenic Hemangioendothelioma).* Letter to Editor. Am J Surg Pathol 2011;35:108.
- Carter JM, Weiss SW, Linos K, et al. *Superficial CD34-positive fibroblastic tumor: report of 18 cases of a distinctive low-grade mesenchymal neoplasm of intermediate (borderline) malignancy.* Mod Pathol 2014;27:294-3.
- Stanford's Surgical Pathology Criteria 2008: Epithelioid Sarcoma.
- Hornick JL, Dal Cin P, Fletcher CD. *Loss of INI-1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma.* Am J Surg Pathol 2009;33:542-50.
- Rossi S, Orvieto E, Furlanetto A, et al. *Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody.* Mod Pathol 2004;17:547-52
- Pusztaszeri MP, Seelentag W, Bosman FT. *Immunohistochemical expression of endothelial marker CD31, CD34, von Willebrand Factor, and Fli-1 in normal human tissues.* J Histochem Cytochem 2006;54:385-95.